

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
24 June 2021 (24.06.2021)



(10) International Publication Number
WO 2021/127500 A1

(51) International Patent Classification:

A61K 39/395 (2006.01) C12P 21/08 (2006.01)
C07K 16/28 (2006.01)

(21) International Application Number:

PCT/US2020/066107

(22) International Filing Date:

18 December 2020 (18.12.2020)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

62/951,723 20 December 2019 (20.12.2019) US
62/983,155 28 February 2020 (28.02.2020) US
63/054,717 21 July 2020 (21.07.2020) US

(71) Applicant: MOMENTA PHARMACEUTICALS, INC.

[US/US]; 301 Binney Street, Cambridge, Massachusetts 02142 (US).

(72) Inventors: KURTAGIC, Elma; c/o Momen-

ta Pharmaceuticals, Inc., 301 Binney Street, Cambridge, Massachusetts 02142 (US). MEADOR, James W. III; c/o Momen-
ta Pharmaceuticals, Inc., 301 Binney Street, Cambridge,

Massachusetts 02142 (US). BENEDUCE, Christopher; c/o Momen-
ta Pharmaceuticals, Inc., 301 Binney Street, Cambridge, Massachusetts 02142 (US).

(74) Agent: BYCHOWSKI, Meaghan E. et al.; Choate, Hall &

Stewart LLP, Two International Place, Boston, Massachusetts 02110 (US).

(81) Designated States (unless otherwise indicated, for every

kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every

kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,

(54) Title: ANTIBODIES AGAINST INTEGRIN ALPHA 11 BETA 1




FIGURE 1

(57) Abstract: The present disclosure includes antibodies that specifically bind integrin alpha 11 beta 1 ($\alpha 11\beta 1$), as well as methods of making and using such antibodies. In some embodiments, an anti- $\alpha 11\beta 1$ antibody, or antigen-binding fragment thereof, is a monoclonal antibody, or antigen-binding fragment thereof. The present disclosure also provides use of such antibodies to treat fibrotic disorders and/or cancers.

[Continued on next page]

EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*